[ Inside the business ]

ACXP stock analysis

ACXP · Acurx Pharmaceuticals, Inc.

Pharmaceutical preparations.

Watch: a leadership change.

The future, in 7 questions

01 What's priced in?Not available

Needs today's sales, share count and price.

02 Is the wave rising?Synthetic biology · 0.6×
'20'21'22'23'24'2536
#10 of 20 mentioning it
03 Will customers keep buying?No customer data
No customer over 10%
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Not enough data
06 Can it fund itself?1.4 yrs of cash
05 yrs10+ yrs
Shares +85.5%/yrDebt $0
07 What could break it?2 to watch
  • Going-concern warning
  • Heavy dilution

From SEC filings, price and Radar. Not advice.

The record

Early signals

Quiet.

A leadership change was filed on Nov 13.

What could go wrong

Steadier than most.

It has moved -2.0× the market. In the 2022 rate shock it fell 31% while the market fell 24%. Debt is covered by cash.

Speculative check

Speculative.

Speculative: going-concern warning; operating loss, cash flowing out of operations, under $1B in sales; penny stock: under $5 a share with under $6M revenue. Cash runway: 1.4 years.

What they sell

Not broken out.

The filings don't split revenue by product in structured data.

Where each dollar goes

Not available.

Cost lines aren't reported in a comparable form.

Its market

1.5× the economy.

The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Not applicable.

Cash flow patterns don't describe a life cycle for banks and insurers, or the totals aren't reported.

Earnings quality

Can't score.

The inputs aren't in its structured filings.

Competitive advantage

Not measurable.

Returns on capital can't be computed from its filings (common for banks and insurers).

Future bets

Not reported.

No research, equipment or commitment figures in its structured filings.

All figures from Acurx Pharmaceuticals, Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.